TY - JOUR
T1 - Documento de consenso de asma grave en adultos. Actualización 2020
AU - Álvarez-Gutiérrez, Francisco Javier
AU - Blanco-Aparicio, Marina
AU - Plaza, Vicente
AU - Cisneros, Carolina
AU - García-Rivero, Juan Luis
AU - Padilla, Alicia
AU - Pérez-de Llano, Luis
AU - Perpiñá, Miguel
AU - Soto-Campos, Gregorio
N1 - Funding Information:
Los autores agradecen el soporte técnico y metodológico prestado por GOC Networking durante el proceso de redacción del documento inicial y el soporte y colaboración de Medical Statistics Consulting (MSC) en el proceso de actualización de las recomendaciones, así como la colaboración de la Dra. Blanca Piedrafita (MSC) en la coordinación y edición del manuscrito actualizado. Los autores de este manuscrito no han recibido aportación económica. El soporte técnico y metodológico ha sido financiado por SEPAR a través de los fondos del Foro Autonómico del Asma.
Publisher Copyright:
© 2020 Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
PY - 2020/7
Y1 - 2020/7
N2 - Severe asthma is a heterogeneous syndrome with multiple clinical variants, and is the last step in terms of disease severity. The prevalence of severe asthma among asthmatic patients varies from country to country and it is estimated that 50% of these severe patients have poor disease control. Optimal management requires correct diagnosis and follow-up, and the patient must be offered the best treatment available, taking into account new pharmacological advances such as monoclonal antibodies. This consensus process emerged from the desire to offer our patients the best possible management and the chance to minimize symptoms. The proposed recommendations are the result of a nominal consensus process performed throughout 2019, and validated in successive revisions. © 2020 Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
AB - Severe asthma is a heterogeneous syndrome with multiple clinical variants, and is the last step in terms of disease severity. The prevalence of severe asthma among asthmatic patients varies from country to country and it is estimated that 50% of these severe patients have poor disease control. Optimal management requires correct diagnosis and follow-up, and the patient must be offered the best treatment available, taking into account new pharmacological advances such as monoclonal antibodies. This consensus process emerged from the desire to offer our patients the best possible management and the chance to minimize symptoms. The proposed recommendations are the result of a nominal consensus process performed throughout 2019, and validated in successive revisions. © 2020 Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
KW - Diagnosis
KW - Monoclonal antibodies
KW - Recommendations
KW - Severe asthma
KW - Tracing
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85096384721&partnerID=8YFLogxK
U2 - 10.1016/j.opresp.2020.03.005
DO - 10.1016/j.opresp.2020.03.005
M3 - Artículo de revisión
AN - SCOPUS:85096384721
SN - 2659-6636
VL - 2
SP - 158
EP - 174
JO - Open Respiratory Archives
JF - Open Respiratory Archives
IS - 3
ER -